Multiomics Analysis of Malignant Pleural Mesothelioma Reveals the Immunological Microenvironment Associated with MTAP Loss and Immunotherapy Outcomes.
Certain immune markers in mesothelioma tumors may predict which patients will benefit from combination immunotherapy, offering a path toward more personalized treatment.
A multiomics analysis of malignant pleural mesothelioma (n=52 WGS cohort + nationwide C-CAT validation) identified immune-active tumor microenvironment features associated with response to nivolumab+ipilimumab, including high T-cell receptor diversity, CD8+ T-cell infiltration, and M1 macrophage enrichment. MTAP loss was identified as a candidate biomarker associated with immune activation and a higher ICI response rate in the validation cohort, warranting prospective investigation as a companion biomarker.
What the study was
- Study design
- retrospective_multicohort_multiomics
- Category
- precision_oncology_genomic_medicine
- Maturity
- Validated
- Journal
- Clinical Cancer Research
Why it surfaced
Novel multiomics biomarker discovery (MTAP loss as ICI predictor) in a rare high-unmet-need cancer; Clin Cancer Res publication; dual-cohort validation from National Cancer Center Japan plus nationwide C-CAT registry.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.